Empowered Funds LLC lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 24.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 384,538 shares of the biopharmaceutical company’s stock after selling 126,411 shares during the period. Empowered Funds LLC’s holdings in Halozyme Therapeutics were worth $24,853,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also modified their holdings of the business. Acadian Asset Management LLC acquired a new position in Halozyme Therapeutics in the first quarter valued at about $195,000. Hsbc Holdings PLC raised its stake in shares of Halozyme Therapeutics by 117.1% in the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock valued at $522,000 after acquiring an additional 5,448 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 174 shares during the last quarter. Baird Financial Group Inc. lifted its holdings in shares of Halozyme Therapeutics by 6.2% in the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock worth $577,000 after acquiring an additional 650 shares during the last quarter. Finally, Jump Financial LLC purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $620,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
HALO has been the topic of a number of research analyst reports. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. HC Wainwright restated a “buy” rating and set a $95.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. UBS Group reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Finally, Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Eight equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $81.60.
Insider Transactions at Halozyme Therapeutics
In related news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $71.75, for a total transaction of $1,435,000.00. Following the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $55,088,215. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 74,102 shares of company stock valued at $5,205,798. 2.50% of the stock is currently owned by corporate insiders.
Halozyme Therapeutics Stock Up 2.4%
Shares of NASDAQ HALO opened at $83.44 on Wednesday. The stock has a market cap of $9.90 billion, a P/E ratio of 30.01, a PEG ratio of 0.34 and a beta of 0.84. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics, Inc. has a 12-month low of $57.67 and a 12-month high of $84.44. The business’s fifty day simple moving average is $73.66 and its 200-day simple moving average is $70.69.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. During the same period last year, the business posted $1.11 earnings per share. Halozyme Therapeutics’s revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Featured Stories
- Five stocks we like better than Halozyme Therapeutics
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
